Senseonics Holdings (SENS) AI Stock Analysis

• Market Cap: $433.64M
• Dividend Yield: N/A
• Average Volume (3M): 7.19M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.75
• Revenue Growth: 1.64%
• EPS Growth: 16.02%
• Country: US
• Employees: 117
• Sector: Healthcare
• Sector Strength: 37
• Industry: Medical - Devices
• EPS (TTM): -0.02
• Shares Outstanding: 754,291,100
• 10 Day Avg. Volume: 9,289,844
• 30 Day Avg. Volume: 7,193,344
• PEG Ratio: -0.33
• Price to Book (P/B): 10.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.70
• Enterprise Value/Market Cap: 0.89
• Enterprise Value/Revenue: 4.19
• Enterprise Value/Gross Profit: 227.15
• Enterprise Value/Ebitda: -1.41
• 1Y Price Target: $1.22
• Price Target Upside: 121.82% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 51 Neutral
• Price Target: $0.50 ▼(-9.09%Downside)

Senseonics Holdings' overall score reflects ongoing financial challenges despite positive earnings call sentiment. Financial instability, marked by negative margins and high debt, is the primary concern. However, strategic collaborations and revenue growth provide a positive outlook, balancing the score.

Positive Factors

Market Expansion

Senseonics is poised for accelerated growth following the U.S. launch of Eversense 365, its year-long implantable CGM.

Partnerships

Abbott recently took a 5% stake in Senseonics, which came with a right of first negotiation and quarterly updates on Senseonics’ R&D programs.

Product Innovation

Senseonics has introduced the first and only implantable CGM, Eversense 365, which offers a full year of monitoring compared to 7-15 days for other CGM offerings.

Negative Factors

Financial Performance

Senseonics reported a net loss of $15.5M in 4Q24, which was better than the forecasted net loss of $23.9M.

Revenue Seasonality

Revenue is expected to show greater seasonality, significantly influenced by annual insurance deductible limits and out-of-pocket costs resetting in January.

Senseonics Holdings Business Overview & Revenue Model

Company Description

Senseonics Holdings, Inc., a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company has a collaboration agreement with the University Hospitals Accountable Care Organization. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

How the Company Makes Money

Senseonics Holdings generates revenue primarily through the sale of its Eversense CGM systems and related supplies. The company's revenue model is based on direct sales to healthcare providers and distribution partnerships that facilitate the delivery of its products to end-users. Significant partnerships, such as those with medical device distributors and healthcare providers, play a crucial role in expanding the market reach and accessibility of the Eversense system. Additionally, Senseonics may earn revenue from licensing agreements and collaborations with other companies in the diabetes care industry, although these represent a smaller portion of their overall revenue.

Senseonics Holdings Financial Statement Overview

Summary

Senseonics Holdings is experiencing challenges typical of a growing company in the medical devices industry, with significant operational losses impacting both profitability and cash flow. While there has been some revenue growth and improvement in equity standing, high debt levels and negative cash flows underscore the need for strategic adjustments. Continued focus on improving operational efficiency and managing debt will be crucial for future financial health.

Income Statement

Senseonics Holdings has shown some revenue growth, with a 5.76% increase in TTM revenue compared to the previous year. However, the company is facing significant profitability challenges, as evidenced by negative EBIT and EBITDA margins. The TTM net profit margin remains deeply negative at -312.34%, reflecting ongoing struggles with high operational losses.

Balance Sheet

The company's balance sheet shows a concerning debt-to-equity ratio due to negative equity in prior years, though it has improved to a positive equity position recently. The TTM equity ratio is 40.35%, indicating a moderate level of equity relative to total assets. However, the high total debt relative to equity remains a potential risk factor for financial stability.

Cash Flow

While the operating cash flow is negative, indicating cash outflows from core operations, the free cash flow has improved slightly over the past year. The TTM operating cash flow to net income ratio is less concerning given the net income losses, but cash flow remains a key area for improvement to ensure sustainability.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	22.47M	22.39M	16.39M	13.68M	4.95M
Gross Profit	533.00K	3.09M	2.73M	-811.00K	-17.37M
EBITDA	-68.70M	-48.01M	161.81M	-284.51M	-157.86M
Net Income	-78.62M	-60.39M	142.12M	-302.47M	-175.17M
Balance Sheet
Total Assets	100.44M	138.22M	177.67M	198.93M	35.92M
Cash, Cash Equivalents and Short-Term Investments	74.60M	109.46M	144.01M	129.91M	18.00M
Total Debt	61.05M	47.78M	74.65M	63.30M	62.70M
Total Liabilities	116.99M	64.77M	180.25M	384.46M	180.00M
Stockholders Equity	-16.55M	73.45M	-2.58M	-185.53M	-144.08M
Cash Flow
Free Cash Flow	-62.70M	-70.51M	-66.62M	-56.29M	-67.60M
Operating Cash Flow	-60.47M	-70.16M	-66.31M	-56.08M	-67.42M
Investing Cash Flow	32.84M	89.71M	26.88M	-148.75M	-181.00K
Financing Cash Flow	26.83M	20.37M	41.76M	220.08M	-10.13M

Senseonics Holdings Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.55
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SENS, the sentiment is Neutral. The current price of 0.55 is above the 20-day moving average (MA) of 0.52, above the 50-day MA of 0.52, and below the 200-day MA of 0.58, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 55.29 is Neutral, neither overbought nor oversold. The STOCH value of 55.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SENS.

Senseonics Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DXCM	78 Outperform	$34.01B	66.80	23.72%	―	9.11%	-17.87%
Sector *	65 Neutral	¥355.44B	11.35	-2.99%	2.49%	11.76%	-10.21%
LIVN	61 Neutral	$2.36B	30.62	-19.69%	―	7.97%	-592.40%
OM	52 Neutral	$311.72M	―	-86.53%	―	-7.84%	42.34%
SENS	51 Neutral	$433.64M	―	-161.19%	―	1.64%	16.02%
TNDM	48 Neutral	$1.03B	―	-92.31%	―	27.65%	-28.22%
NNOX	46 Neutral	$331.56M	―	-30.11%	―	15.32%	15.73%

Senseonics Holdings Corporate Events

Senseonics Holdings Approves Director Elections and Proposals

At the Annual Meeting on May 21, 2025, Senseonics Holdings‘ stockholders voted on three proposals. The election of four directors was approved, with all nominees elected to serve until the 2028 annual meeting. Additionally, the stockholders approved the compensation for the company’s named executive officers and ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Holdings Announces Major Stock Offering Agreement

On May 15, 2025, Senseonics Holdings, Inc. announced an underwriting agreement with TD Securities and Barclays Capital to issue and sell 100,000,000 shares of common stock at $0.50 per share, with an option for underwriters to purchase an additional 15,000,000 shares. The expected net proceeds of approximately $45.4 million, or $52.45 million if the option is exercised, will fund the launch of Eversense 365, development of pipeline products, and general corporate purposes. The offering is part of a shelf registration and includes a concurrent private placement with Abbott Laboratories for up to $25 million. The closing is expected on May 19, 2025, subject to customary conditions.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.

Senseonics Holdings Enters Agreement with Abbott Laboratories

On May 15, 2025, Senseonics Holdings entered into a securities purchase agreement with Abbott Laboratories to sell up to $25 million of its common stock in a private placement, contingent upon the closing of a proposed public offering. This strategic move includes granting Abbott certain negotiation rights for potential future transactions, which could impact the company’s operational and market strategies. The agreement reflects Senseonics’ efforts to strengthen its financial position and explore strategic opportunities, potentially affecting stakeholders and the company’s industry positioning.

The most recent analyst rating on (SENS) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Senseonics Holdings stock, see the SENS Stock Forecast page.